Lorlatinib vs crizotinib in treatment-naive patients with advanced ALK + non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study. J Clin Oncol. 2024; 42 - Solomon, BJ
17 Abstract LBA8503